Literature DB >> 30318260

Pharmacological treatments of neuropathic pain: The latest recommendations.

N Attal1.   

Abstract

We provide an up-to-date review of the pharmacological treatment of neuropathic pain with emphasis on the latest evidence-based recommendations for its pharmacological treatment. Drugs proposed as first line include tricyclic antidepressants (particularly amitriptyline), serotonin-norepinephrine reuptake inhibitors (particularly duloxetine), pregabalin and gabapentin. Second line treatments include lidocaine plasters and capsaicin high concentration patches for peripheral neuropathic pain only, and tramadol. Third line treatments include strong opioids and botulinum toxin A (for peripheral neuropathic pain). Perspectives include the development of new compounds and a more personalized therapeutic approach, which is made possible by recent progress in the assessment and understanding of neuropathic pain.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Neuropathic pain; Personalized medicine; Pharmacotherapy; Recommendations

Mesh:

Substances:

Year:  2018        PMID: 30318260     DOI: 10.1016/j.neurol.2018.08.005

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  25 in total

1.  Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats.

Authors:  L P Legakis; L Karim-Nejad; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2020-05-08       Impact factor: 4.530

2.  Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain.

Authors:  Levent Hacısüleyman; Bülent Saraç; Ziad Joha
Journal:  Turk J Pharm Sci       Date:  2022-06-27

3.  Evaluation of the Effect of Uridine Diphosphate-Glucuronosyltransferases (UGT) Inhibition by Valproic Acid on Vixotrigine Pharmacokinetics in Healthy Volunteers.

Authors:  Yuan Zhao; Mona Kotecha; Helen Finnigan; Michael Serenko; Himanshu Naik
Journal:  Clin Drug Investig       Date:  2022-08-31       Impact factor: 3.580

4.  Sex Differences in CGRP Regulation and Function in the Amygdala in a Rat Model of Neuropathic Pain.

Authors:  Peyton Presto; Volker Neugebauer
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

5.  α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.

Authors:  Zixuan Wang; Stefano Martellucci; Alicia Van Enoo; Dana Austin; Cohava Gelber; Wendy M Campana
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

Review 6.  Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies.

Authors:  Katharine N Gurba; Rida Chaudhry; Simon Haroutounian
Journal:  CNS Drugs       Date:  2022-05-05       Impact factor: 6.497

7.  Chronic Nerve Injuries and Delays in Surgical Treatment Negatively Impact Patient-reported Quality of Life.

Authors:  John M Felder; Ivica Ducic
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-05-21

8.  Adjunctive effect of the serotonin 5-HT2C receptor agonist lorcaserin on opioid-induced antinociception in mice.

Authors:  Salvador Sierra; Kumiko M Lippold; David L Stevens; Justin L Poklis; William L Dewey; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2020-01-24       Impact factor: 5.273

9.  Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model.

Authors:  Xingchen Dong; Huanhuan Li; Min Pei; Jie Tan; Ganjun Chen; Santai Li; Zuobin Xie; Qi Wang; Guifeng Wang; Yi-Li Chen; Chunhe Wang
Journal:  FEBS Open Bio       Date:  2022-05-03       Impact factor: 2.792

Review 10.  Sex differences in pain along the neuraxis.

Authors:  Peyton Presto; Mariacristina Mazzitelli; Riley Junell; Zach Griffin; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2022-03-21       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.